IBCSG Trial 22-00 Serum Substudy

Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in Serum Samples of Patients Participating in Trial IBCSG 22-00

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02393833

Enrollment

136

Registered

2015-03-19

Start date

2002-06-01

Completion date

2018-03-06

Last updated

2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Vascular endothelial growth factor (VEGF), Vascular cell adhesion molecule-1 (VCAM-1), HER2-ECD

Brief summary

The serum protein research study is a substudy of the core study 'Maintenance Chemotherapy in Hormone Non-responsive Breast Cancer'. This substudy is an evaluation of blood proteins and their relationship to breast cancer treatment. It will assess the levels of Vascular Endothelial Growth Factor (VEGF), Soluble HER2 Protein (NRP, neu-related protein) and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples of patients' blood at different time points. The goal is to evaluate differences in serum levels between patients receiving the maintenance chemotherapy and those who do not. The serum levels will be also examined to determine if they vary during the three year period of evaluation. In addition, the serum levels of patients who have a recurrence of their breast cancer will be compared with those who remain disease free. The information obtained from these studies will enable breast cancer physicians to better tailor therapies for future patients.

Detailed description

The Serum Substudy will assess the levels of Vascular Endothelial Growth Factor (VEGF), Soluble HER2 Protein (NRP, neu-related protein) and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in patients' serum samples at different time points. VEGF: Angiogenesis plays a central role in tumor progression of solid neoplasia. The switch from the avascular to the vascular phase is generally accompanied by rapid primary tumor growth and local invasiveness. Furthermore, angiogenesis is also necessary both at the beginning and end of the development of distant metastasis and is implicated in the phenomenon of dormant micrometastases. Antiangiogenic peptides may be altered in the serum or urine of cancer patients. In a study of 144 breast cancer patients, angiogenic protein basic fibroblast growth factor was abnormally elevated in the urine in 29% of cases and in the serum in 10%. Another angiogenic protein, vascular endothelial factor (VEGF), was abnormally elevated in the serum in over 70% of these breast cancer patients (4). Since platelets bind VEGF, platelet values will also be assayed. HER2-ECD: No data are available regarding the presence of serum HER2-ECD (NRP) levels in c-erbB2 negative tumors, but the extracellular domain of the c-erbB2 oncogene product (NRP) is detectable in sera of 30-60% of patients with cerbB2 positive tumors. Many reports have correlated the elevated serum levels of the cerbB2 with gene amplification and c-erbB2 overexpression in tumor. These data support the hypothesis that the level of NRP protein can reflect the presence of c-erbB2 positive cells and that modification of the factor can predict a decrease of c-erbB2 positive cells during standard adjuvant chemotherapy. Moreover, change in the detectable NRP during the maintenance phase can suggest a possible modification in the biology and/or behaviour of hypothetic micrometastasis. VCAM-1: In tumors, endothelial VCAM-1 play a major role in the adhesion of leukocytes to the endothelium, suggesting a relationship between cellular adhesion and angiogenesis. Soluble VCAM-1 has been implicated in the mediation of angiogenesis and some studies support the hypothesis that VCAM-1 provides surrogate markers for endothelial activation and angiogenesis occurring during cancers. Recently, VCAM-1 serum levels have been associated with microvessel density and response to endocrine therapy.

Interventions

PROCEDUREBlood samples collection

Blood samples to be collected at the following time points: 1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.) 2. Months 12, 18 and 36 after start of induction chemotherapy 3. At time of confirmatory evidence of progression

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient must be randomized to the core protocol. Written informed consent for the serum substudy must be signed and dated by the patient and investigator * Patient must not have begun CM maintenance (if randomized to CM maintenance)

Exclusion criteria

* Patient not randomized to the core protocol * Patient already begun CM maintenance (if randomized to CM maintenance)

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline to 18 months in serum VEGF values	18 months	To evaluate differences from baseline (after completion of induction chemotherapy but before commencement of CM Maintenance for patients randomized to CM Maintenance) to 18 months after the start of induction chemotherapy in serum VEGF values between patients in the Observation Group and those in the low dose Cyclophosphamide Methotrexate (CM) Maintenance Group.
Change from baseline to 18 months in serum VCAM-1 values	18 months	To evaluate differences from baseline (after completion of induction chemotherapy but before commencement of CM Maintenance for patients randomized to CM Maintenance) to 18 months after the start of induction chemotherapy in serum VCAM-1 values between patients in the Observation Group and those in the low dose Cyclophosphamide Methotrexate (CM) Maintenance Group.
Change from baseline to 18 months in serum NRP values	18 months	To evaluate differences from baseline (after completion of induction chemotherapy but before commencement of CM Maintenance for patients randomized to CM Maintenance) to 18 months after the start of induction chemotherapy in serum NRP values between patients in the Observation Group and those in the low dose Cyclophosphamide Methotrexate (CM) Maintenance Group.

Secondary

Measure	Time frame	Description
Change from baseline to 12 and 36 months in serum VEGF values	12 & 36 months	To compare the differences from baseline to 12 and 36 months in serum VEGF values in the two randomized groups.
Change from baseline to 12 and 36 months in serum VCAM-1 values	12 & 36 months	To compare the differences from baseline to 12 and 36 months in serum VCAM-1 values in the two randomized groups.
Change from baseline to 12 and 36 months in serum NRP values	12 & 36 months	To compare the differences from baseline to 12 and 36 months in serum NRP values in the two randomized groups.
Change in serum VEGF values from last measurement before progression to measurement at time of confirmatory evidence of progression	Baseline,12-, 18- or 36-months & progression	To compare VEGF values before and after progression in the two randomized groups.
Change in serum VCAM-1 values from last measurement before progression to measurement at time of confirmatory evidence of progression	Baseline,12-, 18- or 36-months & progression	To compare VCAM-1 values before and after progression in the two randomized groups.
Change in serum NRP values from last measurement before progression to measurement at time of confirmatory evidence of progression	Baseline,12-, 18- or 36-months & progression	To compare NRP values before and after progression in the two randomized groups.

Countries

Italy, Nigeria, Peru

Contacts

STUDY_CHAIRAron Goldhirsch, Prof.

IEO Milano

STUDY_CHAIRGiuseppe Viale, Prof.